Market Cap
$25.0B
LH
LABCORP HOLDINGS INC.
$305.98 ▲ +0.45%
Prev close $304.60Market cap$25.0B
ConsensusBuy
12-mo target$344.81 (+12.7%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)34 New Institutional Positions16 Institutional ExitsCongressional Activity (4) Healthcare & Medical Devices
Snapshot
The big-picture read on LH right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (78%)
Inst. Holders
50 funds
Inst. Value
$16.6B
Inst. Activity
34 buys / 16 sells
Insider Activity
$0.00 buy / $8.2M sell
Insider Net $
-$8.2M
SEC Reports
15
Congressional
7 trades
Price chart 30d -7.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 10, 2026 SEC
Labcorp held its 2026 Investor Day, reaffirming full-year 2026 guidance and providing a long-term outlook through 2029.
8-K — Impact 5/10
Sep 10, 2026 short_volume
Short Volume: LH — 59.8% short (0.4M / 0.6M)
Short: 379,437 | Exempt: 661 | TRF Vol: 634,501 | Short Ratio: 59.8% | Off-exchange volume (dark poo
Sep 1, 2026 Insider
Oyegunwa Akinbolade was granted 750 shares
EVP, CIO & CTO
Sep 1, 2026 Insider
Vaughn Bryan T was granted 1,500 shares
EVP and President, Diagnostics
Sep 1, 2026 Insider
Aug 28, 2026 SEC Meltzer Jonathan C was granted 900 shares
EVP, COO
Labcorp filed an 8-K announcing that management will participate in a fireside chat at the Morgan Stanley 24th Annual Gl
8-K — Impact 2/10
Aug 25, 2026 Congress
Aug 19, 2026 SEC April McClain Delaney sell
$100,001 - $250,000 — House
President & CEO Adam H. Schechter and Director Kerrii B. Anderson executed open-market sales totaling $2.45M (0.009% of
CLUSTER — Impact 2/10
Analyst ratings buy % -1.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
78% rate it Buy or better · 27 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 21, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Sep 11, 2026 | UBS | MAINTAIN | Buy | 55% |
| Sep 11, 2026 | Barclays | MAINTAIN | Equal-Weight | 54% |
| Aug 4, 2026 | Piper Sandler | MAINTAIN | Neutral | 54% |
| Aug 3, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Jul 31, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Jul 31, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Jul 31, 2026 | Barclays | MAINTAIN | Equal-Weight | 54% |
| Jul 13, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
| Jul 13, 2026 | Baird | MAINTAIN | Outperform | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 9 | 12 | 6 | 0 | 0 | 78% | |
| Aug 1, 2026 | 9 | 12 | 6 | 0 | 0 | 78% | |
| Jul 1, 2026 | 10 | 13 | 5 | 0 | 0 | 82% | |
| Jun 1, 2026 | 10 | 12 | 6 | 0 | 0 | 79% | |
| May 1, 2026 | 10 | 13 | 6 | 0 | 0 | 79% | |
| Apr 1, 2026 | 10 | 13 | 6 | 0 | 0 | 79% | |
| Mar 1, 2026 | 10 | 13 | 6 | 0 | 0 | 79% | |
| Feb 1, 2026 | 10 | 13 | 6 | 0 | 0 | 79% |
Price targets
Where 16 covering analysts think LH trades over the next 12 months.
$344.81 +12.7% upside Buy
Current$305.98 Low$293.00 Median$352.50 High$385.00 16 analysts
$293.00$385.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
15 SEC filing reports analyzed · 2 bullish, 1 bearish, 0 mixed, 12 neutral · avg impact 3.3/10.
NEUTRAL8-K5/10
Labcorp held its 2026 Investor Day, reaffirming full-year 2026 guidance and providing a long-term ou
Sep 10, 2026
NEUTRAL8-K2/10
Labcorp filed an 8-K announcing that management will participate in a fireside chat at the Morgan St
Aug 28, 2026
NEUTRALCLUSTER2/10
President & CEO Adam H. Schechter and Director Kerrii B. Anderson executed open-market sales totalin
Aug 19, 2026
NEUTRAL8-K2/10
Labcorp announced it will host an Investor Day on September 10, 2026, where management will discuss
Aug 17, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 10, 2026
short_volume
Short Volume: LH — 59.8% short (0.4M / 0.6M)
Short: 379,437 | Exempt: 661 | TRF Vol: 634,501 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
Sep 7, 2026
dark_pool
Dark Pool: LH — 1.4M shares, 46,640 trades
Week starting 2026-09-07. Total ATS volume: 1,406,120 shares across 46,640 trades.
Aug 31, 2026
other
Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity
Enhanced digital experience designed to improve visibility, simplify workflows and support faster decision-making BURLINGTON, N.C., Aug. 31, 2026 /PRN
Aug 31, 2026
dark_pool
Dark Pool: LH — 0.8M shares, 41,854 trades
Week starting 2026-08-31. Total ATS volume: 842,524 shares across 41,854 trades.
Aug 24, 2026
dark_pool
Dark Pool: LH — 1.1M shares, 41,532 trades
Week starting 2026-08-24. Total ATS volume: 1,108,298 shares across 41,532 trades.
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $4.65 | $4.49–$4.73 | 11.3% | -0.0% | 10↑ 0↓ | $3.8B | 13 |
| Next Q | $4.45 | $4.37–$4.53 | 9.4% | +0.0% | 10↑ 0↓ | $3.7B | 13 |
| Current FY | $18.35 | $18.10–$18.48 | 11.6% | +0.0% | 1↑ 2↓ | $14.7B | 18 |
| Next FY | $19.84 | $18.74–$20.43 | 8.1% | +0.1% | 6↑ 0↓ | $15.5B | 18 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $4.650 | — |
| 7d ago | $4.650 | — |
| 30d ago | $4.651 | -0.001 |
| 60d ago | $4.663 | -0.012 |
| 90d ago | $4.590 | +0.060 |
Institutional ownership
Which big funds own LH (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $16.6B total value (59,177,392 shares) as of 2026-Q2. Top holders: Erste, BlackRock,, VANGUARD. Net buying activity: 34 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Erste Asset Management GmbH | 0 | $0.00 | 0.0% | — |
| BlackRock, Inc. | 6,574,261 | $1.8B | 11.1% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,362,254 | $1.5B | 9.1% | — |
| VICTORY CAPITAL MANAGEMENT INC | 4,837,573 | $1.4B | 8.2% | — |
| STATE STREET CORP | 3,907,656 | $1.1B | 6.6% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3,678,798 | $1.0B | 6.2% | — |
| Boston Partners | 3,051,690 | $854.2M | 5.2% | ADD +28.8% |
| Allspring Global Investments Holdings, LLC | 2,236,957 | $635.0M | 3.8% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,188,890 | $610.4M | 3.7% | — |
| Select Equity Group, L.P. | 1,981,948 | $554.9M | 3.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Boston Partners | ADD | 2,368,796 | 3,051,690 | +28.8% | $854.2M |
| FMR LLC | ADD | 1,288,411 | 1,904,870 | +47.8% | $533.4M |
| NORGES BANK | NEW | — | 810,093 | — | $226.8M |
| Amundi | DOUBLED | 274,184 | 596,662 | +117.6% | $167.1M |
| EARNEST PARTNERS LLC | ADD | 313,073 | 476,506 | +52.2% | $133.4M |
| ALLIANCEBERNSTEIN L.P. | TRIM | 877,428 | 418,385 | -52.3% | $111.6M |
| Squarepoint Ops LLC | ADD | 140,165 | 258,438 | +84.4% | $72.4M |
| MILLENNIUM MANAGEMENT LLC | ADD | 124,573 | 228,043 | +83.1% | $63.9M |
| Russell Investments Group, Ltd. | ADD | 96,436 | 141,635 | +46.9% | $39.7M |
| Point72 Asset Management, L.P. | TRIM | 259,566 | 137,444 | -47.0% | $38.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 50 transactions. Net -$8.2M — $0.00 bought, $8.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Oyegunwa Akinbolade | EVP, CIO & CTO | AWARD | 750 | — | — |
| Sep 1, 2026 | Vaughn Bryan T | EVP and President, Diagnostics | AWARD | 1,500 | — | — |
| Sep 1, 2026 | Meltzer Jonathan C | EVP, COO | AWARD | 900 | — | — |
| Sep 1, 2026 | Caveney Brian J | EVP, Pres of BLS, CMO & CSO | AWARD | 3,000 | — | — |
| Aug 17, 2026 | ANDERSON KERRII B | Director | SELL | 3,000 | $318.02 | $954.1K |
| Aug 11, 2026 | Schechter Adam H | President & CEO | SELL | 4,669 | $320.37 | $1.5M |
| Aug 4, 2026 | Summy Amy B. | EVP, Chief Marketing Officer | SELL | 924 | $306.74 | $283.4K |
| Aug 3, 2026 | Wilkinson Peter J | SVP, Chief Accounting Officer | EXERCISE | 1,338 | $209.25 | $280.0K |
| Aug 3, 2026 | Wilkinson Peter J | SVP, Chief Accounting Officer | SELL | 1,338 | $309.23 | $413.8K |
| Aug 3, 2026 | Wilkinson Peter J | SVP, Chief Accounting Officer | SELL | 82 | $309.22 | $25.4K |
Congressional trades
LH trades disclosed by members of Congress, with disclosure delay.
2 members · 3 buys / 4 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | April McClain Delaney | D | HOUSE | SELL | $100,001 - $250,000 | Laboratory Corp of America Holdings | Sep 10, 2026(17d) |
| Aug 7, 2026 | April McClain Delaney | D | HOUSE | SELL | $1,001 - $15,000 | Laboratory Corp of America Holdings | Sep 10, 2026(35d) |
| Aug 6, 2026 | April McClain Delaney | D | HOUSE | SELL | $1,001 - $15,000 | Laboratory Corp of America Holdings | Sep 10, 2026(36d) |
| Aug 5, 2026 | April McClain Delaney | D | HOUSE | SELL | $1,001 - $15,000 | Laboratory Corp of America Holdings | Sep 10, 2026(37d) |
| Feb 19, 2026 | Anthony Wied | R | HOUSE | BUY | $15,001 - $50,000 | Laboratory Corp of America Holdings | Mar 12, 2026(22d) |
| Feb 11, 2026 | April McClain Delaney | D | HOUSE | BUY | $1,001 - $15,000 | Laboratory Corp of America Holdings | Mar 11, 2026(29d) |
| Feb 4, 2026 | April McClain Delaney | D | HOUSE | BUY | $1,001 - $15,000 | Laboratory Corp of America Holdings | Mar 11, 2026(36d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for LH.
Shares short
2,448,617
Settlement Sep 15, 2026
Change vs prior
+16.4%
Semi-monthly cycle
Days to cover
3.3
At avg daily volume
Of shares outstanding
≈3.0%
Estimate — not % of float
All LH filing & press-release reports (15)
- 8-K reportSep 10, 2026
- 8-K reportAug 28, 2026
- CLUSTER reportAug 19, 2026
- 8-K reportAug 17, 2026
- 8-K reportAug 14, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 7, 2026
- 8-K reportJul 30, 2026
- 8-K reportJul 10, 2026
- 8-K reportJun 30, 2026
- 8-K reportApr 30, 2026
- DEFA14A reportApr 10, 2026
- 8-K reportApr 9, 2026
- CLUSTER reportMar 5, 2026
- CLUSTER reportMar 3, 2026